A plain-language, continually updated guide from Dr. Matt Chalmers’ clinical reference on hormones and peptides.
Not offered at Pillars of Wellness. SLU-PP-332 has never been tested in a single human being. It has no established safe human dose, is prohibited by WADA, and its own developers at Saint Louis University have stated it is not ready for human use. This page is provided strictly for research education — it is not a product we sell, prescribe, or recommend.
SLU-PP-332 is a small molecule (not a peptide, despite often being discussed alongside them) developed at Saint Louis University that activates a group of receptors called ERRα, ERRβ, and ERRγ all at once. It works completely differently than the peptides discussed elsewhere on this site: instead of activating a receptor on the outside of a cell, it goes straight to the DNA level, directly turning on genes involved in building new mitochondria and burning fat. In animal studies, this activation pattern has been described in the scientific literature as an “exercise mimetic” — mice given the compound ran roughly 70% farther than untreated controls.
A 2025 research paper introducing a related compound explicitly noted that SLU-PP-332 “lacks oral bioavailability” — meaning oral capsules and tablets sold commercially are unlikely to produce any meaningful biological effect at all, regardless of what’s claimed.
Beyond the lack of any human trial data, even the practical logistics of using this compound are unresolved. SLU-PP-332 doesn’t dissolve well in the standard sterile water peptides are normally mixed with, and the research community has split into several inconsistent, unvalidated workaround methods — none of which have been studied for safety in humans. On top of that, animal research has flagged real theoretical safety concerns worth knowing about, including possible effects on heart tissue remodeling, liver enzymes, and cancer risk (since the same ERR receptors this compound activates are also overexpressed in several cancers). Given all of this, our honest position is that SLU-PP-332 isn’t ready for clinical use, and we don’t offer it.
SLU-PP-332 is not FDA-approved for any indication and remains in preclinical research with no completed human trials of any phase. It is prohibited under WADA’s anti-doping rules (Section S4). This page describes preclinical research findings only — it is not a claim about effects in humans and not an offer to treat any condition or to provide this compound.
SLU-PP-332 remains in preclinical research. Animal studies have shown it activates ERR receptor signaling and downstream PGC-1α activity — the same pathway activated by aerobic exercise — which is why it has been described as an “exercise mimetic” in the scientific literature. This is preclinical, animal-model research; there are no completed controlled human clinical trials.
No. Given the complete absence of human safety data and the compound developers’ own statement that it is not ready for human use, we do not offer, prescribe, or recommend SLU-PP-332. This page exists purely to answer the research questions people have about it.
This page draws on The Pillars Path: A Root-Cause Guide to Hormones, Peptides, and Metabolic Health by Dr. Matt Chalmers — Pillars of Wellness’ clinical reference on hormone and peptide therapy.
